Raymond James & Associates Atreca, Inc. Transaction History

Raymond James & Associates

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$0.88 - $1.22 $21 - $29	-24 Reduced 0.03%	77,500 $75,000
Q4 2022 Feb 08, 2023	SELL	$0.78 - $1.68 $4,875 - $10,500	-6,250 Reduced 7.46%	77,524 $62,000
Q2 2022 Aug 12, 2022	BUY	$1.56 - $3.25 $32,760 - $68,250	21,000 Added 33.45%	83,774 $150,000
Q1 2022 May 11, 2022	BUY	$1.61 - $5.2 $101,066 - $326,424	62,774 New	62,774 $199,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.